BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16164630)

  • 1. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
    Zager RA
    Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.
    Johnson AC; Becker K; Zager RA
    Am J Physiol Renal Physiol; 2010 Aug; 299(2):F426-35. PubMed ID: 20504881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral iron nephrotoxicity: potential mechanisms and consequences.
    Zager RA; Johnson AC; Hanson SY
    Kidney Int; 2004 Jul; 66(1):144-56. PubMed ID: 15200421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory effects of iron sucrose in chronic kidney disease.
    Agarwal R
    Kidney Int; 2006 Apr; 69(7):1259-63. PubMed ID: 16609688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release.
    Zager RA; Johnson AC; Hanson SY; Lund S
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F290-7. PubMed ID: 15494544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous iron sucrose changes the intraperitoneal homeostasis.
    Breborowicz A; PoĊ‚ubinska A; Kupczyk M; Wanic-Kossowka M; Oreopoulos DG
    Blood Purif; 2009; 28(1):53-8. PubMed ID: 19325240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
    Connor JR; Zhang X; Nixon AM; Webb B; Perno JR
    PLoS One; 2015; 10(5):e0125272. PubMed ID: 25973894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Subclinical" gentamicin nephrotoxicity: a potential risk factor for exaggerated endotoxin-driven TNF-alpha production.
    Zager RA
    Am J Physiol Renal Physiol; 2007 Jul; 293(1):F43-9. PubMed ID: 17442725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.
    Zager RA; Johnson AC; Hanson SY; Wasse H
    Am J Kidney Dis; 2002 Jul; 40(1):90-103. PubMed ID: 12087566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
    Zager RA
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S24-31. PubMed ID: 17699373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral iron therapy exacerbates experimental sepsis.
    Zager RA; Johnson AC; Hanson SY
    Kidney Int; 2004 Jun; 65(6):2108-12. PubMed ID: 15149323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
    Auerbach M; Al Talib K
    Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative effect of several intravenous iron complexes in the rat.
    Bailie GR; Schuler C; Leggett RE; Li H; Li HD; Patadia H; Levin R
    Biometals; 2013 Jun; 26(3):473-8. PubMed ID: 23681275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ischemic proximal tubular injury primes mice to endotoxin-induced TNF-alpha generation and systemic release.
    Zager RA; Johnson AC; Hanson SY; Lund S
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F289-97. PubMed ID: 15798091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
    Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
    Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.